REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Peptide Library

Snap-8

Acetyl Octapeptide-3 / SNAP-8 Peptide

Beauty & Skincare

SNAP-8 (Acetyl Octapeptide-3, also marketed as Acetyl Glutamyl Heptapeptide-1) is a topical cosmetic peptide consisting of eight amino acids that modulates the SNARE complex responsible for neurotransmitter release at the neuromuscular junction. Developed by Lipotec as an extension of the hexapeptide Argireline concept, SNAP-8 is marketed as a topical alternative to botulinum toxin for reducing expression lines and wrinkles. It competitively inhibits SNARE complex formation, theoretically reducing muscle contraction intensity and thereby diminishing dynamic wrinkles.

Mechanism of Action

Octapeptide that mimics the N-terminal of SNAP-25, a key protein in the SNARE complex responsible for neurotransmitter release at neuromuscular junctions. Competitively inhibits SNARE complex formation, reducing muscle contraction intensity and thereby reducing expression lines.

Research Protocols

For research purposes only. Not medical advice.

Topical application only. Used at 3-10% concentration in serums applied twice daily to expression-line areas (forehead, crow's feet, glabella). Not injected. Continuous use required for maintained effect.

Research Notes

Clinical Research Status

SNAP-8 has been evaluated in manufacturer-sponsored clinical studies showing wrinkle depth reduction of up to 63% after 28 days of regular application at concentrations of 3-10% in cream formulations. Independent peer-reviewed clinical data is limited compared to manufacturer claims, with most published evidence coming from in vitro SNARE complex inhibition assays rather than controlled clinical trials. It is widely available in cosmetic formulations globally and does not require regulatory approval for topical cosmetic use.

Key Published Findings

In vitro studies demonstrate that SNAP-8 inhibits SNARE complex assembly by competing with SNAP-25 (Synaptosomal-Associated Protein of 25 kDa) for incorporation into the exocytosis machinery. Catecholamine release assays in chromaffin cells show dose-dependent reduction in vesicular fusion and neurotransmitter release at relevant peptide concentrations. The eight-amino acid sequence provides enhanced stability and potentially greater SNARE complex affinity compared to the shorter six-amino acid Argireline sequence.

Safety Profile

SNAP-8 has an excellent safety profile for topical application, with no systemic absorption concerns at cosmetic concentrations and no reported sensitization or irritation in patch testing studies. Unlike injectable botulinum toxin, topical SNAP-8 cannot produce muscle paralysis, ptosis, or other serious adverse effects associated with neuromuscular blockade. It is considered suitable for sensitive skin and periorbital use, with no reported phototoxicity or photoallergic reactions.

Comparison to Related Compounds

SNAP-8 is an elongated version of Argireline (Acetyl Hexapeptide-3), with two additional amino acids theoretically providing greater potency and stability in SNARE complex inhibition. Both peptides target the same mechanism but cannot replicate the complete muscle paralysis achieved by botulinum toxin injection, offering instead a modest reduction in muscle contraction intensity. Compared to Matrixyl which stimulates collagen production, SNAP-8 addresses a completely different aspect of aging (dynamic wrinkles vs. structural collagen loss) and the two are complementary in formulations.

Community Observations

Skincare communities generally report subtle but noticeable improvements in forehead lines and crow's feet with consistent use over 4-8 weeks. Users frequently note that SNAP-8 works best as part of a comprehensive anti-aging routine rather than as a standalone treatment, managing expectations relative to injectable alternatives. DIY skincare formulators commonly work with SNAP-8 solutions at 3-10% concentration, noting that higher concentrations do not necessarily produce proportionally better results.

Half-Life

N/A (topical)

Reconstitution

N/A (topical formulation)

Storage

Lyophilized

Room temperature. Protect from light.

Reconstituted

Store at room temperature. Stable in formulation for 12+ months.

US Legal Status

Cosmetic ingredient (unregulated)

Also Known As

Acetyl Octapeptide-3SNAP-8 Peptide

PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer